Proteolix

ProfoundBio Readies for Next Phase of Growth with Management Team Additions and Advisory Board Appointment

Retrieved on: 
星期四, 十一月 2, 2023
Research, Thought Leadership, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Oncology, IPO, Pharmacyclics, Catalent, Alder, Therapy, Hematology, Nutcracker, MBS, Head, CMC, Seagen, Lundbeck, University of California, Acquisition, PTK7, Protein, Economics, Lundbeck Seattle Biopharmaceuticals, Yale University, Immunotherapy, Growth, SITC, ADC, Division, University, Biology, Amgen, Baxter International, Internal medicine, Merrill (company), Business, Keck Graduate Institute, Society for Immunotherapy of Cancer, Genentech, Society, Cancer, Seattle, University of Southern California, Coronavirus Scientific Advisory Board, Fine chemical, Management, Biochemistry, Proteolix, Chiron, Spacecraft, Western Washington University

We are thrilled to welcome Erin and Kevin to our leadership team as we plan for this next stage of growth.

Key Points: 
  • We are thrilled to welcome Erin and Kevin to our leadership team as we plan for this next stage of growth.
  • In addition, as chair of our Scientific Advisory Board, Lori brings decades of clinical thought-leadership and strategic product development experience in ADCs.
  • We look forward to working alongside them.”
    ProfoundBio also announced additional changes to the company's executive team.
  • Co-founders Tae Han and Xiao Shang will take on the roles of chief strategy officer and head of CMC, respectively.

Atomwise Strengthens its Management Team, Adds Veteran Biopharma Leader David Thomson, Ph.D. as Chief Scientific Officer and Two Additional Senior Appointments

Retrieved on: 
星期二, 一月 25, 2022
Molecule, Triplet, Stanford University, SAN, Boehringer Ingelheim, VP, Industry, United States Air Force Scientific Advisory Board, Stanford University centers and institutes, Therapy, Artificial intelligence, General counsel, Cancer, Pharming, BI, Entrepreneurship, Computer science, Alkermes, Technology, Texas Tech University College of Agricultural Sciences & Natural Resources, Corporation, IPO, AbbVie, Eli Lilly, Board of directors, Deep learning, Nasdaq, Company, Associate, Multimedia, Ropes & Gray, Drug discovery, Alkermes (company), Pharmacyclics, Juno Therapeutics, Proteolix, CMO, Juno, Growth, Leadership, Strategic planning, Machine learning, Cell, CEO, Intellectual property, S.A, View, Drug development, ALKS, Onyx Pharmaceuticals, D. E. Shaw Research, Board, Management, Medical device, Pharmaceutical industry, Research, Science, Nature

Additional management team appointments include Jonathan Barr as Chief Financial Officer and Jeffrey Cerio, Pharm.D., J.D.

Key Points: 
  • Additional management team appointments include Jonathan Barr as Chief Financial Officer and Jeffrey Cerio, Pharm.D., J.D.
  • "I'm thrilled to join Atomwise as Chief Scientific Officer.
  • The Atomwise discovery engine solves this key problem by repeatedly delivering multiple high-quality chemical starting points," said Dr. Thomson.
  • Dr. Thomson has more than 30 years experience in senior and executive roles in the biopharma industry.

Amphista Therapeutics Appoints New Chairman, Joshua T. Brumm

Retrieved on: 
星期二, 九月 21, 2021
Proteolix, Therapy, Amphisbaena, TPD, NASDAQ, Notre Dame, Patient, Zeltiq Aesthetics, Board, Morgan Stanley, CEO, University, Myopathy, Growth, Pharmacyclics, DYN, Nicki, Citigroup Global Markets Japan, Technology, IPO, Dyne, CFO, General partnership, COO, Management

GLASGOW, Scotland, Sept. 21, 2021 /PRNewswire/ -- Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the appointment of Joshua T. Brumm as its new Independent Chairman, succeeding Satish Jindal.

Key Points: 
  • GLASGOW, Scotland, Sept. 21, 2021 /PRNewswire/ -- Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the appointment of Joshua T. Brumm as its new Independent Chairman, succeeding Satish Jindal.
  • Amphista's CEO Dr Nicola Thompson said, "On behalf of the Amphista team I am thrilled to welcome someone of Josh's calibre to the Board.
  • Josh Brumm, Amphista's new Chairman, commented on his appointment, "I am delighted to join Amphista as its Chairman.
  • Josh Brumm is the president and CEO of Dyne Therapeutics, Inc. (NASDAQ: DYN), a leading muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases.

Amphista Therapeutics Appoints New Chairman, Joshua T. Brumm

Retrieved on: 
星期二, 九月 21, 2021
Proteolix, Therapy, Amphisbaena, TPD, NASDAQ, Notre Dame, Patient, Zeltiq Aesthetics, Board, Morgan Stanley, CEO, University, Myopathy, Growth, Pharmacyclics, DYN, Nicki, Citigroup Global Markets Japan, Technology, IPO, Dyne, CFO, General partnership, COO, Management

GLASGOW, Scotland, Sept. 21, 2021 /PRNewswire/ -- Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the appointment of Joshua T. Brumm as its new Independent Chairman, succeeding Satish Jindal.

Key Points: 
  • GLASGOW, Scotland, Sept. 21, 2021 /PRNewswire/ -- Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the appointment of Joshua T. Brumm as its new Independent Chairman, succeeding Satish Jindal.
  • Amphista's CEO Dr Nicola Thompson said, "On behalf of the Amphista team I am thrilled to welcome someone of Josh's calibre to the Board.
  • Josh Brumm, Amphista's new Chairman, commented on his appointment, "I am delighted to join Amphista as its Chairman.
  • Josh Brumm is the president and CEO of Dyne Therapeutics, Inc. (NASDAQ: DYN), a leading muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases.

Tocagen Appoints Lori Kunkel, M.D. as Acting Chief Medical Officer

Retrieved on: 
星期四, 十一月 15, 2018
Biotechnology, Health, AbbVie Inc., Business, Proteolix, Pharmacyclics, Onyx Pharmaceuticals

has been named acting chief medical officer, effective November 26, 2018.

Key Points: 
  • has been named acting chief medical officer, effective November 26, 2018.
  • Asha Das, M.D., senior vice president and chief medical officer will be leaving the company effective November 23, 2018 to allow her to focus on unforeseen and immediate personal matters.
  • Among other responsibilities, Dr. Kunkel previously served as acting chief medical officer of Loxo Oncology, Inc, chief medical officer of Pharmacyclics LLC, acquired by AbbVie Inc., and chief medical officer of Proteolix, Inc., acquired by Onyx Pharmaceuticals.
  • In connection with Dr. Kunkel's appointment as acting chief medical officer of Tocagen, Dr. Kunkel will be temporarily leaving the board of directors of Tocagen in order for the company to maintain compliance with the Nasdaq listing rules regarding independent directors.

ESSA Pharma Enhances R&D Capabilities with Two New Key Hires

Retrieved on: 
星期二, 四月 24, 2018
Carfilzomib, Epoxides, Morpholines, Peptides, Moigne, Proteolix, Sanofi, Economy of France, Biotechnology, Chemistry, Raymond J. Deshaies, Craig M. Crews

Zhou and Le Moigne to ESSA," said David R. Parkinson, ESSA Pharma's President and Chief Executive Officer.

Key Points: 
  • Zhou and Le Moigne to ESSA," said David R. Parkinson, ESSA Pharma's President and Chief Executive Officer.
  • Prior to joining ESSA, he was Vice President of Chemistry at Cleave Biosciences, Group Leader at Proteolix and Scientist at Cytokinetics.
  • Over his career, he contributed to the discovery and development of KYPROLIS (carfilzomib), ONX0914 and omecamtiv mecarbil.
  • Prior to joining ESSA, he served as Senior Director of Pharmacology at Cleave Biosciences, and previously held scientific roles at Sanofi, where Dr.